Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.
about
Pharmacological interventions for apathy in Alzheimer's diseasePersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsLong-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review.Diagnosis and treatment of dementia: the fourth canadian consensus conference.Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?Pathogenesis and treatment of vascular cognitive impairment.Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.Benefits and risks of add-on therapies for Alzheimer's disease.Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia.Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Description of general practitioners' practices when suspecting cognitive impairment. Recourse to care in dementia (Recaredem) study.Detecting and Managing Neuropsychiatric Symptoms in DementiaTrends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010.California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines.Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Effects of Acetylcholinesterase Inhibitors on Balance and Gait Functions and Orthostatic Hypotension in Elderly Patients With Alzheimer Disease.[Dementia and otorhinolaryngologic practice].Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease.Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder
P2860
Q24185815-B997B5D6-C7BA-4E1D-9272-A1C4F89670ACQ26997299-AFAD0605-33B0-4A02-AABF-B0BF2EB51FD4Q35006354-7FB8D262-125E-4C2F-98F0-BF8891CC69F9Q36204169-BFCF5A07-622E-4962-BB5C-ED716115885EQ37693169-D7873812-BC59-4AB5-834C-A0608476D965Q38252709-AEAA0773-DA1E-424A-9832-4AAFE2F54C28Q38297016-BE1C490A-C943-47B4-B4E9-4F7F25D0CD69Q38364828-3540918A-47DE-47CB-94B6-5FE985E2F0A2Q38391086-A0E35056-6DCA-4A3B-8D3A-A57D38B54D42Q38566169-224B07C1-A816-4A10-9038-758672645A3BQ38620338-C1B1BC0A-A2B4-48B5-BDC4-A7DCB781C5A0Q38627971-541BE6FA-D126-4EB3-A71E-C1A20AE32E5EQ38737187-AE7C6544-CD02-4277-966A-B15185EF0DB9Q38797428-E8CCCB1B-D0D8-42AC-84C6-0421538815F5Q38906350-6633D087-BF90-43DD-BE08-59086D02B360Q39415447-FD1A4CDB-8C67-4625-B047-1F4A1C2BB54AQ40477054-90508F0F-2C1F-45DA-9F9C-2C678921B13EQ42139411-B32B9050-C18B-4B41-8787-40520DE1FF24Q43625820-D82670C4-B3B3-4A1F-917F-EC3D85F242C9Q46561794-7EE7592B-7945-4380-9DE9-C145DE2C6374Q47851611-B620FF66-DEE7-4DEA-A76E-E9B9402CEDD1Q48167336-20FEEB58-8C7E-4C25-906D-11442A8DCBC7Q48536715-A466BBE2-B760-436B-A163-C40B3127844CQ50354620-7C411617-ECFB-476E-9D02-85F11FF920A8Q51154144-BD29B4CB-051F-48AE-B18B-0559C9153092Q53377510-FE895B60-D0DC-46FB-8ED4-8694AEEC8626Q58567918-36FA6A4B-55B7-4B31-9D82-0B920C894F8A
P2860
Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@en
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@nl
type
label
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@en
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@nl
prefLabel
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@en
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@nl
P2860
P921
P356
P1476
Pharmacological recommendation ...... nd Treatment of Dementia 2012.
@en
P2093
Nathan Herrmann
P2860
P2888
P356
10.1186/ALZRT201
P407
P433
P577
2013-07-08T00:00:00Z
P5875
P6179
1031323873